Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis

Table 3 Drugs in clinical trials for PDAC targeting cancer associated stroma

Compound	Combination	Target	Stage of patients	Trial phase	Ref	Outcome
Vismodegib	Gemcitabine	Hedgehog signaling	Stage IV PDAC	Phase I/II	[150]	Non- significant [151]
PEGPH20	Gemcitabine, nab-paclitaxel,	Hyaluronic acid	Stage IV PDAC	Phase II	[124]	Ongoing
EF-002	Dose escalation	Activity of macrophages	Solid tumor	Phase I	[152]	Ongoing
Paricalcitol	Gemcitabine, nab-paclitaxel	metabolic pathway	Advanced PC	Phase I	[153]	Ongoing
MEDI4736	Gemcitabine, nab-paclitaxel	C-X-C chemokine receptor type 2	Stage IV PDAC	Phase I/II	[154]	Ongoing
Defactinib	PD-1	FAK signaling	Solid tumor	Phase I/II	[155]	Ongoing
GSK2256098	Tremetinib	FAK signaling	PDAC	Phase II	[156]	Ongoing
retinoic acid	Gemcitabine, nab-paclitaxel	Cancer associated fibroblasts	PDAC	Phase I	[157]	Ongoing
AM0010	FOLFOX, 5-FU, leucovorin	Interleukins-10	Solid tumor	Phase III	[158]	Ongoing
Pembrolizumab	Paricalcitol, gemcitabine, nabpaclitaxel	PD-1	Resectable PC	Phase I	[159]	Ongoing
Cabiralizumab	Nivolumab	Colony-stimulating factor-1 receptor	Solid tumor	Phase I	[160]	Ongoing
Sonidegib	Gemcitabine, nab-paclitaxel	Hedgehog signaling	Stage IV PDAC	Phase I/II	[161]	Completed, Data not provided

ISSN: 1476-4598